First Phase 1 Double-Blind, Placebo-Controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Anton, Peter A ^a   Saunders, Terry ^a   Elliott, Julie ^a   Khanukhova, Elena ^a   Dennis, Robert ^a   Adler, Amy ^a,f   Cortina, Galen ^a   Tanner, Karen ^a   Boscardin, John ^a,g   Cumberland, William G ^b   Zhou, Ying ^b   Ventuneac, Ana ^d   Carballo Diéguez, Alex ^d   Rabe, Lorna ^c   McCormick, Timothy ^e   Gabelnick, Henry ^e   Mauck, Christine ^e   McGowan, Ian ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f Translational Science Corp   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; PLACEBO; ANILIDE; ANTIINFECTIVE AGENT; FURAN DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EX VIVO STUDY; FEMALE; GEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VIVO STUDY; MALE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECTUM MUCOSA; SEROLOGY; SEXUAL BEHAVIOR; SIGMOIDOSCOPY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ADULT; BIOPSY; CLINICAL TRIAL; ENDOSCOPY; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; RECTAL DRUG ADMINISTRATION; RECTUM; SERODIAGNOSIS; TIME; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADMINISTRATION, RECTAL; ADULT; ANILIDES; ANTI-INFECTIVE AGENTS; BIOPSY; ENDOSCOPY; FEMALE; FURANS; GELS; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RECTUM; TIME FACTORS;

EID: 80053248640     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023243     Document Type: Article

References (85)

1. Brenchley JM, Douek DC, (2008) HIV infection and the gastrointestinal immune system. Mucosal Immunol 1: 23-30.
2. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, et al. (2010) Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 6: e1000852.
3. Shattock RJ, Haynes BF, Pulendran B, Flores J, Esparza J, (2008) Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 5: e81.
4. Margolis L, Shattock R, (2006) Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol 4: 312-317.
5. Olsson J, Poles M, Spetz AL, Elliott J, Hultin L, et al. (2000) Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines. J Infect Dis 182: 1625-1635.
6. Poles MA, Elliott J, Taing P, Anton PA, Chen IS, (2001) A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol 75: 8390-8399.
7. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, et al. (2000) Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 14: 1761-1765.
8. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092-2098.
9. Anema A, Wood E, Montaner JS, (2008) The use of highly active retroviral therapy to reduce HIV incidence at the population level. CMAJ 179: 13-14.
10. Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 329: 1168-1174.
11. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med.
12. Supervie V, Garcia-Lerma JG, Heneine W, Blower S, (2010) HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A 107: 12381-12386.
13. New York City Dept.of Helath and Mental Hygene (2010) Women, unprotected anal sex and HIV risk. NYC Vital Signs 9.
14. Phillips DM, Taylor CL, Zacharopoulos VR, Maguire RA, (2000) Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 62: 149-154.
15. Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, et al. (1999) Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Infect 26: 564-571.
16. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360: 971-977.
17. AVAC: Global Advacocy for HIV Prevention (2009) Understanding the results from trials of the PRO 2000 microbicide candidate. AVAC.ORG.
18. Kamali A, Byomire H, Muwonge C, Bakobaki J, Rutterford C, et al. (2010) A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex Transm Infect 86: 222-226.
19. HPTN 035 (2010) HPTN 035: Phase II/IIb safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO2000/5 Gel (P) for the prevention of HIV infection in women. http://www.hptn.org/research_studies/hptn035.asp.
20. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, et al. (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359: 463-472.
21. Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, et al. (2008) Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS ONE 3: e3784.
22. Lapenta C, Boirivant M, Marini M, Santini SM, Logozzi M, et al. (1999) Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur J Immunol 29: 1202-1208.
23. McGowan I, Elliott J, Fuerst M, Taing P, Boscardin J, et al. (2004) Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation. J Acquir Immune Defic Syndr 37: 1228-1236.
24. Mosher WD, Chandra A, Jones J, (2005) Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data pp. 1-55.
25. Halperin DT, (1999) Heterosexual anal intercourse: prevalence, cultural factors, and HIV infection and other health risks, Part I. AIDS Patient Care STDS 13: 717-730.
26. Baldwin JI, Baldwin JD, (2000) Heterosexual anal intercourse: an understudied, high-risk sexual behavior. Arch Sex Behav 29: 357-373.
27. Gross M, Holte SE, Marmor M, Mwatha A, Koblin BA, et al. (2000) Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team. J Acquir Immune Defic Syndr 24: 393-398.
28. Skurnick JH, Kennedy CA, Perez G, Abrams J, Vermund SH, et al. (1998) Behavioral and demographic risk factors for transmission of human immunodeficiency virus type 1 in heterosexual couples: report from the Heterosexual HIV Transmission Study. Clin Infect Dis 26: 855-864.
29. Leichliter JS, Chandra A, Liddon N, Fenton KA, Aral SO, (2007) Prevalence and correlates of heterosexual anal and oral sex in adolescents and adults in the United States. J Infect Dis 196: 1852-1859.
30. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, et al. (2001) Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357: 1149-1153.
31. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371: 2109-2119.
32. bu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM Jr, et al. (2008) Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3: e2230.
33. Lingappa JR, Lambdin B, Bukusi EA, Ngure K, Kavuma L, et al. (2008) Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS ONE 3: e1411.
34. Zuckerman RA, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, et al. (2007) Herpes simplex virus (HSV) suppression with Valacyclovir reduces rectal and blood plama HIV-1 levels in HIV-1/HSV-2-seropositive men: A randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 196: 1500-1508.
35. Barnard J, Borkow G, Parniak MA, (1997) The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36: 7786-7792.
36. Balzarini J, Pelemans H, Aquaro S, Perno CF, Witvrouw M, et al. (1996) Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol 50: 394-401.
37. Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, et al. (2005) The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 79: 11179-11186.
38. Goddeeris C, Van den MG, (2008) Free flowing solid dispersions of the anti-HIV drug UC 781 with Poloxamer 407 and a maximum amount of TPGS 1000: investigating the relationship between physicochemical characteristics and dissolution behaviour. Eur J Pharm Sci 35: 104-113.
39. Terrazas-Aranda K, Van HY, Hazuda D, Lewi P, Costi R, et al. (2008) Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother 52: 2544-2554.
40. Lackman-Smith C, Osterling C, Luckenbaugh K, Mankowski M, Snyder B, et al. (2008) Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother 52: 1768-1781.
41. Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, et al. (2006) Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 20: 1237-1245.
42. Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, et al. (2005) The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 79: 11179-11186.
43. Chan DJ, McNally L, (2008) Assays for the determination of HIV-1 load in semen: a review of indications, methods and performance in vitro. Curr HIV Res 6: 182-188.
44. Chan DJ, McNally L, Batterham M, Smith DE, (2008) Relationship between HIV-RNA load in blood and semen in antiretroviral-naive and experienced men and effect of asymptomatic sexually transmissible infections. Curr HIV Res 6: 138-142.
45. Kalichman SC, Di BG, Eaton L, (2008) Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis 35: 55-60.
46. Patton DL, Sweeney YT, Balkus JE, Rohan LC, Moncla BJ, et al. (2007) Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother 51: 1608-1615.
47. Schwartz JL, Kovalevsky G, Lai JJ, Ballagh SA, McCormick T, et al. (2008) A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex Transm Dis 35: 414-419.
48. Schwartz JL, Poindexter A, Wheeless A, Mauck CK, Callahan MM, (2009) Safety evaluation of 1% tenofovir gel in healthy men. Int J STD AIDS 20: 384-386.
49. McGowan I, Elliott J, Cortina G, Tanner K, Siboliban C, et al. (2007) Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 46: 417-425.
50. Ventuneac A, Carballo-Dieguez A, McGowan I, Dennis R, Adler A, et al. (2010) Acceptability of UC781 Gel as a Rectal Microbicide Among HIV-Uninfected Women and Men. AIDS Behav 14: 618-628.
51. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, et al. (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340: c869.
52. Schulz KF, Altman DG, Moher D, (2010) CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. Ann Intern Med 152: 726-732.
53. CONRAD (2006) Investigator's Brochure: Universal Placebo Gel. UC-781. Version 3.0.
54. Shacklett BL, Yang O, Hausner MA, Elliott J, Hultin L, et al. (2003) Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods 279: 17-31.
55. Anton PA, Ibarrondo FJ, Boscardin WJ, Zhou Y, Schwartz EJ, et al. (2008) Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments. Vaccine 26: 4617-4623.
56. Brun JG, Ulvestad E, Fagerhol MK, Jonsson R, (1994) Effects of human calprotectin (L1) on in vitro immunoglobulin synthesis. Scand J Immunol 40: 675-680.
57. Yui S, Mikami M, Yamazaki M, (1995) Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. J Leukoc Biol 58: 650-658.
58. Roseth AG, Aadland E, Jahnsen J, Raknerud N, (1997) Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 58: 176-180.
59. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, et al. (2000) A simple method for assessing intestinal inflammation in Crohn's disease. Gut 47: 506-513.
60. Ibarrondo FJ, Anton PA, Fuerst M, Ng HL, Wong JT, et al. (2005) Parallel Human Immunodeficiency Virus Type 1-Specific CD8+ T-Lymphocyte Responses in Blood and Mucosa during Chronic Infection. J Virol 79: 4289-4297.
61. Hillier SL, Krohn MA, Rabe LK, Klebanoff SJ, Eschenbach DA, (1993) The normal vaginal flora, H2O2-producing lactobacilli, and bacterial vaginosis in pregnant women. Clin Infect Dis 16 (Suppl 4): S273-S281.
62. Clarke JG, Peipert JF, Hillier SL, Heber W, Boardman L, et al. (2002) Microflora changes with the use of a vaginal microbicide. Sex Transm Dis 29: 288-293.
63. Patton DL, Cosgrove Sweeney YT, Rabe LK, Hillier SL, (2002) Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis 29: 581-587.
64. Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, et al. (2007) HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with. AIDS 21: 1263-1272.
65. Richardson-Harman N, Lackman-Smith C, Fletcher PS, Anton PA, Bremer JW, et al. (2009) Multi-site comparison of anti-HIV microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol 47: 3530-3539.
66. Zhang L, He T, Talal A, Wang G, Frankel SS, et al. (1998) In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol 72: 5035-5045.
67. Patterson BK, Landay A, Andersson J, Brown C, Behbahani H, et al. (1998) Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol 153: 481-490.
68. Padian N, Marquis L, Francis DP, Anderson RE, Rutherford GW, et al. (1987) Male-to-female transmission of human immunodeficiency virus. JAMA 258: 788-790.
69. Royce RA, Sena A, Cates W Jr, Cohen MS, (1997) Sexual transmission of HIV. N Engl J Med 336: 1072-1078.
70. Baggaley RF, White RG, Boily MC, (2010) HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 39: 1048-1063.
71. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ, (2009) Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 53: 1797-1807.
72. Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, et al. (2010) HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol 3: 280-290.
73. Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins JE Jr, et al. (2005) A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis 192: 1545-1556.
74. Erickson PI, Bastani R, Maxwell AE, Marcus AC, Capell FJ, et al. (1995) Prevalence of anal sex among heterosexuals in California and its relationship to other AIDS risk behaviors. AIDS Educ Prev 7: 477-493.
75. Misegades L, Page-Shafer K, Halperin D, McFarland W, (2001) Anal intercourse among young low-income women in California: an overlooked risk factor for HIV? AIDS 15: 534-535.
76. Evans BA, Bond RA, MacRae KD, (1988) Sexual behaviour in women attending a genitourinary medicine clinic. Genitourin Med 64: 43-48.
77. Strang J, Powis B, Griffiths P, Gossop M, (1994) Heterosexual vaginal and anal intercourse amongst London heroin and cocaine users. Int J STD AIDS 5: 133-136.
78. Guimaraes MD, Munoz A, Boschi-Pinto C, Castilho EA, (1995) HIV infection among female partners of seropositive men in Brazil. Rio de Janeiro Heterosexual Study Group. Am J Epidemiol 142: 538-547.
79. Rodrigues JJ, Mehendale SM, Shepherd ME, Divekar AD, Gangakhedkar RR, et al. (1995) Risk factors for HIV infection in people attending clinics for sexually transmitted diseases in India. BMJ 311: 283-286.
80. Gates GJ, Sonenstein FL, (2000) Heterosexual genital sexual activity among adolescent males: 1988 and 1995. Fam Plann Perspect 32: 295-7, 304.
81. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, et al. (2007) Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204: 705-714.
82. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, et al. (2003) Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS 17: 53-63.
83. McGowan I, Radford-Smith G, Jewell DP, (1994) Cytokine gene expression in HIV-infected intestinal mucosa. AIDS 8: 1569-1575.
84. Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, et al. (2007) Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: Potential implication for HIV transmission. J Infect Dis 195: 703-710.
85. Hendrix CW, Fuchs EJ, Macura KJ, Lee LA, Parsons TL, et al. (2008) Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin Pharmacol Ther 83: 97-105.